Extracellular vesicles and circulating nucleic acidsOct 17, 2026

Designed tiny cell particles: drug delivery challenges, improvement methods, and potential medical uses

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 18, 2026

Abstract

Current evidence suggests that engineered extracellular vesicles (EVs) are unlikely to replace established lipid nanoparticles or viral vectors across all applications.

Engineered EVs may improve therapeutic performance by addressing challenges such as low cargo levels and rapid clearance by the immune system.
Strategies for enhancing EVs include cargo loading, control of circulation, targeted delivery to specific tissues or cells, and facilitating entry into cells.
Concerns regarding immunogenicity and manufacturing risks are associated with the engineering of EVs.
Recent preclinical and clinical progress indicates that practical limitations exist, including costs, supply chain issues, and cold-chain distribution.
Localized delivery and modulation of the immune environment could be potential areas where engineered EVs may provide distinct advantages.

Simplified

Extracellular vesicle (EV) therapeutics are progressing from broad proof-of-concept studies toward product-specific engineering and clinically defined applications. Native EVs offer biological membrane functions and the capacity to transport diverse molecular cargoes, but their therapeutic performance is limited by low cargo stoichiometry, rapid mononuclear phagocyte system clearance, clearance-dominated biodistribution, and inefficient functional cargo release. This Review examines how EV engineering strategies are used to address these barriers. We compare approaches for cargo loading, circulation control, tissue- and cell-selective targeting, and intracellular delivery, while considering the immunogenicity and manufacturing risks introduced by engineering. We also assess recent preclinical and clinical progress, including programs that were paused or discontinued, and discuss the practical constraints of cost, supply chain, and cold-chain distribution. Current evidence suggests that engineered EVs are unlikely to replace established lipid nanoparticles or viral vectors across all applications. Their near-term value is more likely to arise in localized delivery, immune-microenvironment modulation, complex cargo delivery, and defined cell-targeting settings in which biological membrane functions provide a measurable advantage.

Full Text

Full text is available at the source.

View Full Text ↗

Designed tiny cell particles: drug delivery challenges, improvement methods, and potential medical uses

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief